Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice

British Journal of Pharmacology

Volumn 139, Issue 4, 2003, Pages 755-764

  Isoherranen, Nina ^a   Yagen, Boris ^a,b   Spiegelstein, Ofer ^c   Finnell, Richard H ^c   Merriweather, Michelle ^c   Woodhead, Jose H ^d   Wlodarczyk, Bogdan ^c   White, H Steve ^d   Bialer, Meir ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Anticonvulsant activity; Audiogenic seizures; Metabolism; Pharmacokinetics; Pharmacokinetics in brain; Taurine; Teratogenicity; Valproic acid; Valproyltaurinamides

Indexed keywords

ANTICONVULSIVE AGENT; N ISOPROPYLVALPROYLTAURINAMIDE; N METHYLVALPROYLTAURINAMIDE; N,N DIMETHYLVALPROYLTAURINAMIDE; UNCLASSIFIED DRUG; VALPROYLTAURINAMIDE; VALPROYLTAURINAMIDE DERIVATIVE;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; AUDIOGENIC SEIZURE; BIRTH DEFECT; CONGENITAL MALFORMATION; CONTROLLED STUDY; DEALKYLATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG URINE LEVEL; EMBRYO DEATH; FEMALE; GESTATIONAL AGE; INCIDENCE; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; STRUCTURE ACTIVITY RELATION; TERATOGENICITY;

ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EMBRYONIC AND FETAL DEVELOPMENT; INJECTIONS, INTRAPERITONEAL; MICE; MICE, MUTANT STRAINS; MOLECULAR STRUCTURE; SEIZURES; TERATOGENS; VALPROIC ACID;

EID: 0037664485     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705301     Document Type: Article

References (48)

1. ABU SALACH, O., HADAD, S., HAJ-YEHIA, A., SUSSAN, S. & BIALER, M. (1994). Comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity. Pharm. Res., 11, 1429-1434.
2. BENNETT, G.D., LAU, F., CALVIN, J.A. & FINNELL, R.H. (1997). Phenytoin-induced teratogenesis: a molecular basis for the observed developmental delay during neurulation. Epilepsia, 38, 415-423.
3. BIALER, M., JOHANNESSEN, S.I., KUPFERBERG, H.J., LEVY, R.H., LOISEAU, P. & PERUCCA, E. (2002). Progress report on new antiepileptic drugs: a summary of the sixth EILAT conference on new antiepileptic drugs (EILAT VI). Epilepsy Res., 51, 31-71.
4. BOJIC, U., EHLERS, K., ELLERBECK, U., BACON, C.L., O'DRISCOLL, E., O'CONNELL, C., BEREZIN, V., KAWA, A., LEPEKHIN, E., BOCK, E., REGAN, C.M. & NAU, H. (1998). Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic center. Eur. J. Pharmacol., 354, 289-299.
5. BONHAUS, D.W., LAIRD, H., MIMAKI, T., YAMAMURA, H.I. & HUXTABLE, R.J. (1983). Possible base for anticonvulsant action of taurine. In: Sulfur Amino Acids: Biochemical and Clinical Aspects. ed. Kuriyama, K., Huxtable, R.J. & Iwata, H. pp. 195-209. New York: Alan R. Liss.
6. FINNELL, R.H., BENNETT, G.D., KARRAS, S.B. & MOHL, V.K. (1988). Common hierarchies of susceptibility to the induction of neural tube defects by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology, 38, 313-320.
7. FINNELL, R.H., BENNETT, G.D., SLATTERY, J.T., AMORE, B.M., BAJPAJ, M. & LEVY, R.H. (1995). Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology, 52, 324-332.
8. FINNEY, D.J. (1971). Probit Analysis. 3rd edn Cambridge, U.K.: Cambridge University Press.
9. GIBALDI, M. & PERRIER, D. (1982). Pharmacokinetics. 2nd edn New York: Marcel-Dekker.
10. GOODMAN, H.O., SHIHABI, Z. & OLES, K.S. (1989). Antiepileptic drugs and plasma and platelet taurine in epilepsy. Epilepsia, 30, 201-207.
11. GRILLO, M.P., CHIELLINI, G., TONELLI, M. & BENET, L.Z. (2001). Effect of alpha-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats. Drug Metab. Dispos., 29, 1210-1215.
12. HADAD, S. & BIALER, M. (1995). Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. Pharm. Res., 12, 905-910.
13. HARTLEY, S.G., GOODMAN, H.O. & SHIHABI, Z. (1989). Urinary excretion of taurine in epilepsy. Neurochem. Res., 14, 149-152.
14. HASSEL, B., TAUBOELL, E. & GJERSTAD, L. (2001). Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels. Epilepsy Res., 43, 153-163.
15. ISOHERRANEN, N., WOODHEAD, J., WHITE, H.S. & BIALER, M. (2001). Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia, 42, 831-836.
16. ISOHERRANEN, N., YAGEN, B. & BIALER, M. (2003a). New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr. Opin. Neurol., 16, 203-211.
17. ISOHERRANEN, N., YAGEN, B., SPIEGELSTEIN, O., STEINMAN, A., FINNELL, R.H. & BIALER, M. (2003b). Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma. J. Chromatogr. B, 788, 125-136.
18. JUCHAU, M.R., LEE, Q.P. & FANTEL, A.G. (1992). Xenobiotic biotransformation/bioactivation in organogenesis-stage conceptal tissues: implications for embryotoxicity and teratogenesis. Drug Metab. Rev., 24, 195-238.
19. KANEKO, S., BATTINO, D., ANDERMAN, E., WADA, K., KAN, R., TAKEDA, A., NAKANE, Y., OGAWA, Y., AVANZINI, G., FUMAROLA, C., GRANATA, T., MOLTENI, F., PARDI, G., MINOTTI, L., CANGER, R., DANSKY, L., OGUNI, M., LOPES-CENDAS, I., SHERWIN, A., ANDERMAN, F., SENI, M.-H., OKADA, M. & TERANISHI, T. (1999). Congenital malformations due to antiepileptic drugs. Epilepsy Res., 33, 145-158.
20. KERANEN, T., PARTANEN, V.S.J., KOIVISTO, K., TOKOLA, O., NEUVONEN, P.J. & RIEKKINEN, P.J. (1987). Effects of taltrimide, an experimental taurine derivative, on photoconvulsive response in epileptic patients. Epilepsia, 28, 133-137.
21. KOIVISTO, K., SIVENIUS, J., KERANEN, T., PARTANEN, J., RIEKKINEN, P., GOTHONI, G., TOKOLA, O. & NEUVONEN, P.J. (1986). Clinical trial with an experimental taurine derivative, taltrimide, in epileptic patients. Epilepsia, 27, 87-90.
22. KONTRO, P., LINDEN, I.-B., GOTHONI, G. & OJA, S.S. (1983). Novel anticonvulsant taurine derivatives. In: Sulfur Amino Acids: Biochemical and Clinical Aspects. pp. 211-220. New York: Alan R. Liss.
23. KOTCH, L.E., CHEN, S.-Y. & SULIK, K.K. (1995). Ethanol-induced teratogenesis: free radical damage as a possible mechanism. Teratology, 52, 128-136.
24. KURIYAMA, K. & HASHIMOTO, T. (1998). Interrelationship between taurine and GABA. In: Taurine 3. Cellular and Regulatory Mechanisms. ed. Schaffer, S., Lombardini, J.B. & Huxtable R.J. pp. 329-337. New York: Plenum Press.
25. LAMMER, E.J., SEVER, L.E. & OAKLEY, G.P. (1987). Teratogen update: valproic acid. Teratology, 35, 465-473.
26. LI, Z-Q., YAMAMOTO, Y., MORIMOTO, T., ONO, J., OKADA, S. & YAMATODANI, A. (2000). The effect of pentylenetetrazole-kindling on the extracellular glutamate and taurine levels in the frontal cortex in rats. Neurosci. Lett., 282, 117-119.
27. LINDHOUT, D. & OMTZIGT, J.G.C. (1994). Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia, 35 (Suppl. 4), S19-S28.
28. LOSCHER, W., HORSTERMANN, D., HONACK, D., RUNDFELDT, C. & WAHNSCHAFFE, U. (1993). Transmitter amino acid levels in rat brain regions after amygdala-kindling or chronic electrode implantation without kindling: evidence for a pro-kindling effect of prolonged electrode implantation. Neurochem. Res., 18, 775-781.
29. NAKAYAMA, J., FU, Y.-H., CLARK, A.M., NAKAHARA, S., HAMANO, K., IWASAKI, N., MATSUI, A., ARINAMI, T. & PTACEK, L.J. (2002). A nonsense mutation of the MASS1 gene in a family with febrile and afebrile seizures. Ann. Neurol., 52, 654-657.
30. NAU, H. (1986). Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens. The parent drug and not one of the metabolites assayed is implicated as teratogen. Fundam. Appl. Toxicol., 6, 662-668.
31. NAU, H., HAUCK, R.-S. & EHLERS, K. (1991). Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol., 69, 310-321.
32. NAU, H. & HENDRICKX, A.G. (1987). Valproic acid teratogenesis. ISI Atlas Sci. Pharm., 1, 52-56.
33. OJA, S.S., KONTRO, P., LINDEN, I.-B. & GOTHONI, G. (1983). Anticonvulsant activity of some 2-aminoethanesulphonic acid (taurine) derivatives. Eur. J. Pharmacol., 87, 191-198.
34. PARMAN, T., CHEN, G. & WELLS, P.G. (1998). Free radical intermediates in phenytoin and related temtogens. J. Biol Chem., 273, 25079-25088.
35. PERUCCA, E. (2002). Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs, 16, 695-714.
36. RADATZ, M., EHLERS, K., YAGEN, B., BIALER, M. & NAU, H. (1998). Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res., 30, 41-48.
37. ROGERS, S.W., GAHRNG, L.C. & WHITE, H.S. (1998). Glutamate receptor GluR1 expression is altered selectively by chronic audiogenic seizures in the Frings mouse brain. J. Neurobiol., 35, 209-216.
38. SPIEGELSTEIN, O., BIALER, M., RADATZ, M., NAU, H. & YAGEN, B. (1999a). Asymmetric synthesis and teratogenicity of propylisopropyl acetamide-a CNS-active chiral amide analogue of valproic acid. Chirality, 11, 645-650.
39. SPIEGELSTEIN, O., YAGEN, B. & BIALER, M. (1999b). Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. Epilepsia, 40, 545-552.
40. SHAH, V.P., MIDHA, K.K., FINDJAY, J.W.A., HILL, J.D., HULSE, I.J., MCILVERAY, I.J., MCKAY, G., MILLER, K.J., PATNAIK, R.N., POWELL, M.L., TONELL, A., VISWANATHAN, C.T. & YACOBI, A. (2000). Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res., 17, 1551-1557.
41. SKRADSKI, S.K., CLARK, A.M., JIANG, H., WHITE, H.S., FU, Y.-H. & PTACEK, L.J. (2001). A novel gene causing a Mendelian audiogenic mouse epilepsy. Neuron, 31, 537-544.
42. SNELL, G.D., FEKETE, E. & HUMMEL, K.P. (1948). The relation of mating, ovulation and the estrus smear in the house mouse to the time of day. Anat. Rec., 76, 30-54.
43. TANG, W., BOREL, A.G., FUJIMIYA, T. & ABBOTT, F.S. (1995). Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol., 8, 671-682.
44. TONG, X. & PATSALOS, P.N. (2001). A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in the rat brain. Br. J. Pharmacol., 133, 867-874.
45. UEMURA, S., IENAGA, K., HIGAHIURA, K. & KIMURA, H. (1992). χ-Glutamyltaurine has potent and long-lasting antiepileptic action as demonstrated by intra-amygdaloid injection in amygdala-kindled rats. Brain Res., 594, 347-350.
46. WELLS, P.G., KIM, P.M., LAPOSA, R.R, NICOL, C.J., PARMAN, T. & WINN, L.M. (1997). Oxidative damage in chemical teratogenesis. Mutat. Res., 396, 65-78.
47. WHITE, H.S., PATEL, S. & MELDRUM, B.S. (1992). Anticonvulsant profile of MDL 27,266: an orally active, broad-spectrum anticonvulsant agent. Epilepsy Res., 12, 217-226.
48. WLODARCZYK, B.C., CRAIG, J.C., BENNETT, G.D., CALVIN, J.A. & FINNELL, R.H. (1996). Valproic acid-induced changes in gene expression during neurulation in a mouse model. Teratology, 54, 284-297.